Amyloid-Beta–derived biomarker antibody program
Category
Diagnostics and Personalised Medicine
Register type
Biotech Sanitaria
Company name
Product / Service
Amyloid-Beta–derived biomarker antibody program
Type
Biomarkers
Diagnostic
Therapeutic area
Sistema nervioso central
Properties/Indication
High-specificity monoclonal antibodies targeting a derived amyloid-beta peptide, designed for both detection and therapeutic applications. These antibodies are engineered to bind the peptide with high affinity and minimal cross-reactivity, suitable for ultrasensitive immunoassay technologies as well as potential peptide neutralization strategies. The program aims to support biomarker research, early disease monitoring, and therapeutic intervention by reducing or eliminating circulating levels of the target peptide in Alzheimer’s disease patients.
Application
Intended for use as in vitro diagnostic and research reagents, and as investigational therapeutic antibodies. Applications include integration into ultrasensitive immunoassays for biomarker detection and quantification, clinical and translational research, assay development and validation, and as potential therapeutic agents to modulate circulating levels of the derived amyloid-beta peptide in patients. This program represents the next step in expanding our Alzheimer’s disease peptide-targeted antibody portfolio.
Development phase
R&D
Phases developed in Spain
R&D
Research location
España